Constance Mere, MD
Nephrology · Washington, DCNPI 1205945565
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,190 of the $2,649 with a category attached, or 82.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 94 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$517
- Vifor Pharma, Inc.$327
- Fresenius USA Marketing, Inc.$297
- GSK$227
- Ardelyx, Inc.$223
- AstraZeneca$222
- plus $836 from 16 others
Across 7 payments — averaging $6793.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$48K
What the payments were for
- Speaking & faculty fees$2008%
- Food & beverage$2,19083%
- Education$26010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 17 | $517 |
| Vifor Pharma, Inc. | 7 | $327 |
| Fresenius USA Marketing, Inc. | 13 | $297 |
| GSK | 8 | $227 |
| Ardelyx, Inc. | 8 | $223 |
| AstraZeneca | 6 | $222 |
| Otsuka America Pharmaceutical, Inc. | 7 | $153 |
| OPKO Pharmaceuticals, LLC | 6 | $137 |
| Amgen | 4 | $94 |
| ANI Pharmaceuticals, Inc. | 2 | $63 |
| Calliditas Therapeutics US Inc. | 3 | $62 |
| Akebia Therapeutics Inc | 2 | $49 |
| Viatris Specialty LLC | 2 | $45 |
| Travere Therapeutics, Inc. | 1 | $41 |
| Sanofi | 1 | $38 |
| Leadiant Biosciences, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Biomerieux Inc | 1 | $18 |
| Outset Medical Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,649 in reported general payments places this provider in the 70th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 20 | $111,298 |
| RayaldeeCalcifediol | 41 | $30,828 |
| FarxigaDapagliflozin Propanediol | 28 | $29,761 |
| KerendiaFinerenone | 21 | $28,344 |
| JardianceEmpagliflozin | 25 | $28,138 |
| OzempicSemaglutide | 15 | $15,228 |
| ProcritEpoetin Alfa | 11 | $10,855 |
| TrulicityDulaglutide | 12 | $10,658 |
| Sevelamer Carbonate | 46 | $9,318 |
| SpsSodium Polystyrene Sulfon/Sorb | 30 | $7,229 |
| Calcium Acetate | 54 | $5,339 |
| Nifedipine ErNifedipine | 46 | $1,451 |
| Amlodipine Besylate | 128 | $796 |
| Midodrine Hcl | 21 | $644 |
| Atorvastatin Calcium | 96 | $632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $137 | $30,82841 claims |
| AstraZenecaFarxiga | $222 | $29,76128 claims |
| BayerKerendia | $517 | $28,34421 claims |
| Boehringer IngelheimJardiance | $25 | $28,13825 claims |
| Novo NordiskOzempic | $22 | $15,22815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 62 nephrology providers in District of Columbia.
Other nephrology in Washington
- Ashte CollinsWashington$1M
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.